Cardior: Cardior announces first patient dosed in phase 2 trial
The HF-REVERT study is evaluating efficacy and safety of heart failure therapy
Read full article »
Cardior is a Germany-based biopharmaceutical company that researches and develops RNA-dependent therapies for the treatment of heart diseases.
Read more